FDA
-
-
-
-
-
-
-
Foundation Medicine Receives New ADLT Status for FoundationOne CDx™ from the Centers for Medicare and Medicaid Services (CMS)
-
-
-
-
-
-
-
Foundation Medicine Announces Commercial Availability of FoundationOne CDx™, the First FDA-Approved Comprehensive Genomic Profiling Assay for All Solid Tumors Incorporating Multiple Companion Diagno
-
-
-
-
-
-
-
Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free Survival (PFS) with the Opdivo Plus Yervoy Combination Versus Chemotherapy in First-Line Non-Small Cell Lung Cancer (NSCLC)
-
-
-
-
-
-
-
Foundation Medicine's (FMI) Test to Detect Extensive Number of Cancer Biomarkers Receives FDA Approval, CMS Proposes Coverage
-
-
-
-
-
-
-
Foundation Medicine Announces 2017 Second Quarter Results and Recent Highlights
-
-
-
-
-
-
-
Foundation Medicine Receives Medicare Payment in Non-Small Cell Lung Cancer under a Local Coverage Determination for FoundationOne®, the Company’s Comprehensive Genomic Profiling Assay
-
-
-
-
-
-
-
Foundation Medicine Receives FDA Approval of FoundationFocus™ CDxBRCA as a Companion Diagnostic for Rubraca™ (rucaparib) for the Treatment of Women with Ovarian Cancer
322,943 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

